Debrisoquine

Debrisoquine^[1]
Names

IUPAC name 1,2,3,4-tetrahydroisoquinoline-2-carboximidamide
Identifiers
CAS Number	1131-64-2^Y
3D model (Jmol)	Interactive image
ChEBI	CHEBI:34665^Y
ChEMBL	ChEMBL169901^Y
ChemSpider	2860^Y
DrugBank	DB04840^Y
ECHA InfoCard	100.013.155
KEGG	C13650^Y
MeSH	Debrisoquine
PubChem	2966
UNII	X31CDK040E^Y
InChI InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)^Y Key: JWPGJSVJDAJRLW-UHFFFAOYSA-N^Y InChI=1/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12) Key: JWPGJSVJDAJRLW-UHFFFAOYAE
SMILES [N@H]=C(N)N2Cc1c(cccc1)CC2
Properties
Chemical formula	C₁₀H₁₃N₃
Molar mass	175.23032
Pharmacology
ATC code	C02CC04 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Y verify (what is ^YN ?)
Infobox references

Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug metabolizing enzyme.^[2]

References

↑ Debrisoquine – Compound Summary, PubChem.
↑ Fuhr, U.; Jetter, A.; Kirchheiner, J. (2007). "Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach". Clinical Pharmacology & Therapeutics. 81 (2): 270–283. doi:10.1038/sj.clpt.6100050.

Sympatholytic (and closely related) antihypertensives (C02)

Sympatholytics
(antagonize α-adrenergic
vasoconstriction)

Central

α₂ agonist	Clonidine Guanabenz Guanfacine Methyldopa^# Tiamenidine^‡

Adrenergic release inhibitors	Bethanidine Bretylium Debrisoquine Guanadrel Guanazodine Guanethidine Guanoclor Guanazodine Guanoxabenz Guanoxan

Imidazoline receptor agonist	Moxonidine Rilmenidine Tolonidine

Ganglion-blocking/nicotinic antagonist	Hexamethonium^‡ Mecamylamine Pentolinium Trimethaphan

Peripheral

Indirect

MAOI	Pargyline^‡

Adrenergic uptake inhibitor	Bietaserpine Deserpidine Methoserpidine Rescinnamine Reserpine

Tyrosine hydroxylase inhibitor	Metirosine

Direct

α₁ blockers	Prazosin Indoramin Trimazosin Doxazosin Urapidil

Non-selective α blocker	Phentolamine

Other antagonists

Serotonin antagonist	Ketanserin Lidanserin

Endothelin antagonist (for PH)	dual (Bosentan, Macitentan) selective (Ambrisentan, Sitaxentan)

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

Debrisoquine

See also

References